Education
About Us
Working with TipRanks
Follow Us
4D Molecular Therapeutics, Inc. (FDMT)
:FDMT
FDMT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.87 - $29.27
Previous CloseN/A
Volume165.32K
Average Volume (3M)690.26K
Market Cap
$149.56M
Enterprise Value-$145.20M
Total Cash (Recent Filing)-$23.85M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.12
Next Earnings
May 08, 2025EPS Estimate
-0.87Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.16
Shares Outstanding46,302,406
10 Day Avg. Volume721,889
30 Day Avg. Volume690,259
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)4905.55
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-3.92K
Enterprise Value/Ebitda0.77
Forecast
1Y Price Target
$33.40Price Target Upside1017.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
---
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementThe gene therapy program is on the verge of pivotal trial initiations, highlighting a significant advancement for the company.
Financial HealthFDMT ended 4Q24 with $505.0mm in cash and equivalents, expected to fund operations, showcasing strong financial health.
Safety And Efficacy4D-150’s safety remains highly favorable with less than 3% of patients showing minimal inflammation and 99% remaining steroid-free.
Bears Say
Commercial UncertaintyAnalyst's rating is predicated primarily on currently difficult-to-discern eventual commercial dynamics for an anti-VEGF gene therapy.
Market CompetitionThere is competition from other programs and possible retina business model disruption.
Program Delays4D-175, 4D-725, and 4D-310 remain paused pending additional financing or partnerships, indicating potential delays in these programs.
---
Ownership Overview
14.99% Insiders
13.25% Mutual Funds
1.41% Other Institutional Investors
58.27% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
FDMT FAQ
What was 4D Molecular Therapeutics, Inc.’s price range in the past 12 months?
4D Molecular Therapeutics, Inc. lowest stock price was $2.87 and its highest was $29.27 in the past 12 months.
What is 4D Molecular Therapeutics, Inc.’s market cap?
4D Molecular Therapeutics, Inc.’s market cap is $149.56M.
When is 4D Molecular Therapeutics, Inc.’s upcoming earnings report date?
4D Molecular Therapeutics, Inc.’s upcoming earnings report date is May 08, 2025 which is in 35 days.
How were 4D Molecular Therapeutics, Inc.’s earnings last quarter?
4D Molecular Therapeutics, Inc. released its earnings results on Feb 28, 2025. The company reported -$0.89 earnings per share for the quarter, missing the consensus estimate of -$0.835 by -$0.055.
Is 4D Molecular Therapeutics, Inc. overvalued?
According to Wall Street analysts 4D Molecular Therapeutics, Inc.’s price is currently Undervalued.
Does 4D Molecular Therapeutics, Inc. pay dividends?
4D Molecular Therapeutics, Inc. does not currently pay dividends.
What is 4D Molecular Therapeutics, Inc.’s EPS estimate?
4D Molecular Therapeutics, Inc.’s EPS estimate is -0.87.
How many shares outstanding does 4D Molecular Therapeutics, Inc. have?
4D Molecular Therapeutics, Inc. has 46,302,406 shares outstanding.
What happened to 4D Molecular Therapeutics, Inc.’s price movement after its last earnings report?
4D Molecular Therapeutics, Inc. reported an EPS of -$0.89 in its last earnings report, missing expectations of -$0.835. Following the earnings report the stock price went down -8.609%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics, Inc.?
Currently, no hedge funds are holding shares in FDMT
---
4D Molecular Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.40 (1017.06% Upside)
$33.40 (1017.06% Upside)
Blogger Sentiment
Bullish
FDMT Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 624.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 0.9%
Last 30 Days ▲ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.03%
12-Months-Change
Fundamentals
Return on Equity
-25.95%
Trailing 12-Months
Asset Growth
67.04%
Trailing 12-Months
Company Description
4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics (FDMT) is a biotechnology company focused on developing precision-guided AAV gene therapy vectors and products. The company operates within the healthcare sector, specializing in the design, development, and commercialization of transformative gene therapies for patients with serious genetic diseases. Its core products are based on proprietary technology that enables targeted delivery and enhanced efficacy of gene therapies, aiming to address unmet medical needs across a range of therapeutic areas.
---
FDMT Stock 12 Month Forecast
Average Price Target
$33.40
▲(1017.06% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Adverum Biotechnologies
―
Crispr Therapeutics AG
―
Best Analysts Covering FDMT
1 Year
1 Year Success Rate
5/19 ratings generated profit
1 Year Average Return
-27.94%
reiterated a buy rating last month
Copying Matthew Caufield's trades and holding each position for 1 Year would result in 26.32% of your transactions generating a profit, with an average return of -27.94% per trade.
---